Enhancing antibody efficacy in plants via targeted manipulation of dolichol biosynthesis

通过多萜醇生物合成的靶向操作增强植物中的抗体功效

• 批准号: 481364-2015
• 负责人: Akhtar, Tariq
• 金额: $ 1.82万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=581722
• 关键词: Enhancing; antibody; efficacy; plants; via

PlantForm Corporation is a Canadian company that specializes in turning plants into versatile 'bioreactors' for the production of therapeutic proteins used in the treatment of HIV/AIDS, breast and other forms of cancer. Compared to current animal systems that are used to produce protein based therapeutics, PlantForm's plant-based production system lowers the manufacturing costs considerably. Any advancement in PlantForm's mAbs production efficiency will not only give them a competitive edge in this billion dollar biopharmaceutical market, but lower production costs translate into lower treatment costs for the thousands of Canadians who are affected by such diseases. The objective of this research project is to enhance PlantForm's bioproduction platform by incorporating technology that has recently been developed by Dr. Tariq Akhtar at the University of Guelph. Specifically, this research project aims to improve the yield of functional monoclonal antibodies that can be produced in plants.

PlantForm公司是一家加拿大公司，专门将植物转化为多功能的生物反应器，用于生产用于治疗艾滋病毒/艾滋病、乳腺癌和其他形式癌症的治疗性蛋白质。与目前用于生产基于蛋白质的治疗药物的动物系统相比，PlantForm的基于植物的生产系统大大降低了制造成本。PlantForm的单抗生产效率的任何提高，不仅将使它们在这个价值10亿美元的生物制药市场上获得竞争优势，而且更低的生产成本将转化为数千受此类疾病影响的加拿大人的更低治疗成本。该研究项目的目标是通过采用Guelph大学Tariq Akhtar博士最近开发的技术来增强PlantForm的生物生产平台。具体地说，该研究项目旨在提高可以在植物中生产的功能性单抗的产量。